During the last session, NovoCure Ltd (NASDAQ:NVCR)’s traded shares were 0.72 million, with the beta value of the company hitting 0.71. At the end of the trading day, the stock’s price was $15.75, reflecting an intraday gain of 5.92% or $0.88. The 52-week high for the NVCR share is $24.74, that puts it down -57.08 from that peak though still a striking 30.98% gain since the share price plummeted to a 52-week low of $10.87. The company’s market capitalization is $1.70B, and the average intraday trading volume over the past 10 days was 0.74 million shares, and the average trade volume was 1.02 million shares over the past three months.
NovoCure Ltd (NVCR) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.14. NVCR has a Sell rating from 1 analyst(s) out of 5 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
NovoCure Ltd (NVCR) registered a 5.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.92% in intraday trading to $15.75, hitting a weekly high. The stock’s 5-day price performance is 7.00%, and it has moved by -9.12% in 30 days. Based on these gigs, the overall price performance for the year is 8.92%. The short interest in NovoCure Ltd (NASDAQ:NVCR) is 5.49 million shares and it means that shorts have 5.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $35, which implies an increase of 55.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14.5 and $200 respectively. As a result, NVCR is trading at a discount of -1169.84% off the target high and 7.94% off the low.
NovoCure Ltd (NVCR) estimates and forecasts
Statistics show that NovoCure Ltd has outperformed its competitors in share price, compared to the industry in which it operates. NovoCure Ltd (NVCR) shares have gone up 16.06% during the last six months, with a year-to-date growth rate more than the industry average at 31.28% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 28.30% this quarter and then jump 20.00% in the quarter after that. In the rating firms’ projections, revenue will increase 13.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 143.85M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 147.69M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 127.32M and 133.78M respectively. In this case, analysts expect current quarter sales to grow by 13.00% and then jump by 10.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -22.97%. While earnings are projected to return 29.89% in 2024.
NVCR Dividends
NovoCure Ltd is due to release its next quarterly earnings on 2024-Oct-30. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
NovoCure Ltd insiders own 9.23% of total outstanding shares while institutional holders control 86.56%, with the float percentage being 95.36%. FMR LLC is the largest shareholder of the company, while 330.0 institutions own stock in it. As of 2024-06-30, the company held over 16.14 million shares (or 15.0482% of all shares), a total value of $276.51 million in shares.
The next largest institutional holding, with 12.13 million shares, is of BLACKROCK INC.’s that is approximately 11.3106% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $207.83 million.
